Atea Pharmaceuticals Inc (AVIR)

May 01, 2025

A stock that deserves closer examination: Atea Pharmaceuticals Inc (AVIR) - uspostnews.com

May 01, 2025

May 01, 2025

Atea Pharmaceuticals to Host Virtual HCV KOL Panel on May 14, 2025 - The Manila Times

May 01, 2025

Apr 26, 2025

JPMorgan Chase & Co. Buys 314,015 Shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World

Apr 26, 2025

Apr 26, 2025

Geode Capital Management LLC Lowers Stock Holdings in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World

Apr 26, 2025

Apr 25, 2025

Atea Pharmaceuticals Inc (AVIR) produces promising results - uspostnews.com

Apr 25, 2025

Apr 25, 2025

Financial Health Report: Atea Pharmaceuticals Inc (AVIR)’s Ratios Tell a Tale - DWinneX

Apr 25, 2025

Apr 23, 2025

Atea Pharmaceuticals (AVIR) to Reveal Phase 2 Study Results at E - GuruFocus

Apr 23, 2025

Apr 23, 2025

Atea Pharmaceuticals to Present New Data Showcasing Potential Best-in-Class Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2025 - GlobeNewswire

Apr 23, 2025

Apr 23, 2025

AVIRAtea Pharmaceuticals, Inc. Latest Stock News & Market Updates - Stock Titan

Apr 23, 2025

Apr 22, 2025

A better buy-in window may exist right now for Atea Pharmaceuticals Inc (AVIR) - Sete News

Apr 22, 2025

Apr 22, 2025

Layoff Tracker: Tempest Axes 80% of Workforce - BioSpace

Apr 22, 2025

Apr 18, 2025

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Shares Sold by Vanguard Group Inc. - Defense World

Apr 18, 2025

Apr 17, 2025

Atea Pharmaceuticals expands board, authorizes stock buyback By Investing.com - Investing.com Canada

Apr 17, 2025

Apr 17, 2025

Latham & Watkins Advises Atea Pharmaceuticals in Agreement With Radoff-JEC Group - Latham & Watkins LLP

Apr 17, 2025

Apr 17, 2025

Atea Pharmaceuticals Appoints Howard H. Berman To Board - citybiz

Apr 17, 2025

Apr 17, 2025

Atea Pharmaceuticals Announces Board Changes and Share Buyback - TipRanks

Apr 17, 2025

Apr 17, 2025

Atea Pharmaceuticals Board Approves $25 Million Share Repurchase Program - marketscreener.com

Apr 17, 2025

Apr 17, 2025

Atea Pharmaceuticals expands board, authorizes stock buyback - Investing.com

Apr 17, 2025

Apr 17, 2025

Atea Pharmaceuticals says strategic alternatives process ‘ongoing’ - TipRanks

Apr 17, 2025

Apr 17, 2025

Atea Pharmaceuticals Appoints Howard H. Berman To Board Of Directors And Announces Share Repurchase Program - marketscreener.com

Apr 17, 2025

Apr 17, 2025

Atea Pharmaceuticals Appoints Howard H. Berman to Board of Directors and Announces Share Repurchase Program - GlobeNewswire

Apr 17, 2025

Apr 17, 2025

Atea Pharma Doubles Down: $25M Share Buyback Plan Unveiled as Strategic Review Accelerates - Stock Titan

Apr 17, 2025

Apr 13, 2025

Morgan Stanley Issues Pessimistic Forecast for Atea Pharmaceuticals (NASDAQ:AVIR) Stock Price - Defense World

Apr 13, 2025

Apr 11, 2025

Atea Pharmaceuticals Stock Price, Quotes and Forecasts | NASDAQ:AVIR - Benzinga

Apr 11, 2025

Apr 10, 2025

Atea Pharmaceuticals doses first patient in C-BEYOND, Phase 3 study - MSN

Apr 10, 2025

Apr 09, 2025

Atea Pharmaceuticals Doses First Patient In Phase 3 Trial For Chronic Hepatitis C Treatment - RTTNews

Apr 09, 2025

Apr 09, 2025

Atea Pharmaceuticals Doses First Patient in Late-Stage Study of Hepatitis C Virus Combination Regimen - marketscreener.com

Apr 09, 2025

Apr 09, 2025

Atea Pharmaceuticals Announces Dosing of First Patient in - GlobeNewswire

Apr 09, 2025

Apr 09, 2025

Atea Pharmaceuticals Announces Dosing Of First Patient In C-Beyond, Phase 3 Study Evaluating Regimen Of Bemnifosbuvir And Ruzasvir For Treatment Of Hepatitis C Virus - MarketScreener

Apr 09, 2025

Apr 09, 2025

Breakthrough: Atea's New 8-Week Hepatitis C Treatment Enters Final Trial Stage - Stock Titan

Apr 09, 2025

Apr 05, 2025

HighTower Advisors LLC Purchases Shares of 50,087 Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World

Apr 05, 2025

Apr 01, 2025

Atea Pharmaceuticals board nominee withdrawal ahead of 2025 meeting By Investing.com - Investing.com South Africa

Apr 01, 2025

Apr 01, 2025

Atea Pharmaceuticals board nominee withdrawal ahead of 2025 meeting - Investing.com

Apr 01, 2025

Mar 31, 2025

Driver Notifies Atea Pharmaceuticals of Withdrawal of Notice of Nomination - The Manila Times

Mar 31, 2025

Mar 29, 2025

Charles Schwab Investment Management Inc. Boosts Stock Holdings in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World

Mar 29, 2025

Mar 26, 2025

Atea Pharmaceuticals takes steps to boost shareholder value By Investing.com - Investing.com South Africa

Mar 26, 2025

Mar 26, 2025

Atea Pharmaceuticals takes steps to boost shareholder value - Investing.com

Mar 26, 2025

Mar 26, 2025

Atea Pharma Reviewing Strategic Opportunities After Cutting 25% of Jobs - MarketWatch

Mar 26, 2025

Mar 26, 2025

Atea Pharmaceuticals Highlights Actions Underway to Enhance Shareholder Value - The Manila Times

Mar 26, 2025

Mar 26, 2025

Atea's Bold Restructuring: $15M Cost Savings Plan and Strategic Review Unveiled - Stock Titan

Mar 26, 2025

Mar 26, 2025

Atea Shareholder Seeks Board Change, Plans to Nominate Directors at 2025 Annual Meeting - Marketscreener.com

Mar 26, 2025

Mar 26, 2025

The Radoff-JEC Group Nominates Three Highly Qualified Candidates for Election to the Atea Pharmaceuticals Board of Directors - MarketScreener

Mar 26, 2025

Mar 24, 2025

Connor Clark & Lunn Investment Management Ltd. Raises Stock Holdings in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World

Mar 24, 2025

Mar 22, 2025

Atea Pharmaceuticals Issues Statement Regarding Director Nominations - GlobeNewswire

Mar 22, 2025

Mar 21, 2025

Atea Pharmaceuticals receives notice of director nominations from Bradley Radoff -March 21, 2025 at 05:58 pm EDT - MarketScreener

Mar 21, 2025